Venatorx Pharmaceuticals Presents Data on Investigational Cefepime-Taniborbactam at IDWeek 2022
Venatorx Pharmaceuticals Presents Data on Investigational Cefepime-Taniborbactam at IDWeek 2022
Superior to Meropenem for the Primary Efficacy Endpoint
Safety Profile Consistent with Meropenem
Comments are closed.